Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
5,360
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
5,235 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,360 | +2.4% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 5,235 | +1.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 5,159 | +5.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 4,888 | -4.7% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 5,128 | +14.6% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 4,475 | -3.9% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 4,656 | +6.2% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 4,386 | +7.9% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 4,063 | +5.7% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 3,844 | +3.7% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 3,707 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up core laboratory diagnostics (alinity ci/i/c/m/h/s, architect, glp track) — worldwide revenue ($m)
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Organic / Comparable Sales Growth (%)2.1% · FY2025
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Reported Sales Growth (%)2.4% · FY2025
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Foreign Exchange Impact on Sales Growth (%)0.3% · FY2025
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — U.S. Revenue ($M)1,425 · FY2025
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — International Revenue ($M)3,935 · FY2025
- Core Laboratory — Organic Sales Growth Excl. COVID-19 Testing (%)5.8% · FY2024
- Core Laboratory — COVID-19 Testing Sales ($M)10 · FY2024
Cite this data
StockData. (2026). Abbott Laboratories Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-cl-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.